Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
24.96
+0.14 (0.58%)
At close: Aug 13, 2025, 4:00 PM
25.04
+0.09 (0.34%)
After-hours: Aug 13, 2025, 4:10 PM EDT
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $181.10M in the quarter ending June 30, 2025, with 1.73% growth. This brings the company's revenue in the last twelve months to $705.85M, up 2.25% year-over-year. In the year 2024, Pacira BioSciences had annual revenue of $700.97M with 3.85% growth.
Revenue (ttm)
$705.85M
Revenue Growth
+2.25%
P/S Ratio
1.63
Revenue / Employee
$893,478
Employees
790
Market Cap
1.12B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 700.97M | 25.99M | 3.85% |
Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PCRX News
- 7 days ago - Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Pacira BioSciences Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 20 days ago - Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 - GlobeNewsWire
- 4 weeks ago - Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit - PRNewsWire
- 5 weeks ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation - Accesswire